http://media.peerviewpress.com/000136/podcast/pvi/xml/urology_audio.xml Mon, 05 Oct 2009 14:11:32 -0400 PeerView Urology CME/CNE/CPE Audio Podcast PVI, PeerView Institute for Medical Education http://www.peerviewpress.com Podcast Maker v1.3.8b - http://www.lemonzdream.com/podcastmaker Thought leader perspectives on current clinical advances in medicine. PeerView Press is an independent, professional medical publishing company focused on gathering and reporting information pertaining to clinically relevant advances and developments in the science and practice of medicine. As publishers of PeerView Publications, PeerView Press is solely responsible for the selection of publication topics, the preparation of editorial content and the distribution of all materials it publishes. 2006 PeerView Press, 24 West 40th Street, Suite 950, New York, NY, 10018 webmaster@peerviewpress.com http://podcast.peerviewpress.com/urology/podcast_urologyCME-CNE-CPE_144.jpg PeerView Urology CME/CNE/CPE Audio Podcast http://www.peerviewpress.com 144 144 Science & Medicine CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE no Bernard J. Escudier, MD - Expanding Options for First-Line Treatment of Advanced Kidney Cancer: How Can We Choose the Right Treatment for the Right Patient? PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, an expert discusses the latest clinical trial data on targeted therapies for upfront treatment of metastatic RCC, assesses the clinical implications of these data, and provides recommendations for optimal integration of new agents into the current treatment paradigm for advanced RCC. http://podcast.peerviewpress.com/Urology/PPVNE05963s142.mp3 http://podcast.peerviewpress.com/urology/PPVNE05963s142.mp3 Wed, 12 Aug 2009 15:34:59 -0400 Science, Medicine no 00:15:31 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO CME/CNE/CPE Information - Expanding Options for First-Line Treatment of Advanced Kidney Cancer: How Can We Choose the Right Treatment for the Right Patient? PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Urology/PPVNE05963CMEinfo.pdf http://podcast.peerviewpress.com/urology/PPVNE05963CMEinfo.pdf Wed, 12 Aug 2009 15:34:56 -0400 Science, Medicine no 00:00:00 renal cell carcinoma, RCC, bevacizumab, sunitinib, sorafenib, interferon, VEGF, TKI, pazopanib, ASCO Robert J. Motzer, MD - Established and Emerging Therapies for Renal Cell Carcinoma: Clinical Highlights From the 2009 Meeting in Orlando PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this activity, experts in oncology discuss the latest data on current and emerging therapies for advanced renal cell carcinoma. http://podcast.peerviewpress.com/Urology/PA05679FCs545.mp3 http://podcast.peerviewpress.com/urology/PA05679FCs545.mp3 Wed, 15 Jul 2009 16:01:29 -0400 Science, Medicine no 00:23:35 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 CME/CNE/CPE Information - Established and Emerging Therapies for Renal Cell Carcinoma: Clinical Highlights From the 2009 Meeting in Orlando PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Urology/PA05679FCCMEinfo.pdf http://podcast.peerviewpress.com/urology/PA05679FCCMEinfo.pdf Wed, 15 Jul 2009 16:01:23 -0400 Science, Medicine no 00:00:00 renal cell carinoma, RCC, AVOREN, CALGB, bevacizumab, interferon, TKI, pazopanib, sunitinib, AV-951 Laura S. Wood, RN, MSN, OCN - Early and Aggressive Management of Treatment-Related Adverse Effects Is Essential for Achieving Optimal Clinical Outcome With Targeted Therapies in Patients With Kidney Cancer PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file for full CME/CNE/CPE information. In this program, an expert on kidney cancer provides a concise summary of the key aspects of the biology of renal cell carcinoma (RCC), characteristics of the targeted therapies, and strategies to effectively manage the adverse effects related to these agents. http://podcast.peerviewpress.com/Urology/PA05122FCn205.mp3 http://podcast.peerviewpress.com/urology/PA05122FCn205.mp3 Tue, 10 Mar 2009 16:13:46 -0400 Science, Medicine no 00:18:59 renal cell, targeted, kidney, RCC, mTOR, antiangiogenesis, bevacizumab, sunitinib, everolimus, temsirolimus, sorafenib CME/CNE/CPE Information - Early and Aggressive Management of Treatment-Related Adverse Effects Is Essential for Achieving Optimal Clinical Outcome With Targeted Therapies in Patients With Kidney Cancer PVI, PeerView Institute for Medical Education Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file for full CME/CNE/CPE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Urology/PA05122FCCMEinfo.pdf http://podcast.peerviewpress.com/urology/PA05122FCCMEinfo.pdf Tue, 10 Mar 2009 16:13:43 -0400 Science, Medicine no 00:00:00 renal cell, targeted, kidney, RCC, mTOR, antiangiogenesis, bevacizumab, sunitinib, everolimus, temsirolimus, sorafenib Roger R. Dmochowski, MD - Challenges in Managing Overactive Bladder: A Case-Based Approach PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this CME activity, an expert in the management of overactive bladder discusses diagnosis and treatment of this condition using a case-based format. Management strategies for a patient with comorbidities are also highlighted. http://podcast.peerviewpress.com/Urology/PA04407FCp138.mp3 http://podcast.peerviewpress.com/Urology/PA04407FCp138.mp3 Thu, 29 May 2008 17:39:52 -0400 Science & Medicine no 00:27:25 Incontinence, overactive bladder, micturition, voiding, antimuscarinic, urgency, nocturia, UTI, Kegel, bladder, LUTS CME/CE Information - Challenges in Managing Overactive Bladder: A Case-Based Approach PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Urology/PA04407FCCMEinfo.pdf http://podcast.peerviewpress.com/Urology/PA04407FCCMEinfo.pdf Thu, 29 May 2008 17:38:53 -0400 Science & Medicine no 00:00:00 Incontinence, overactive bladder, micturition, voiding, antimuscarinic, urgency, nocturia, UTI, Kegel, bladder, LUTS Ronald de Wit, MD - Educational Interventions to Improve Outcomes in the Multidisciplinary Treatment of Hormone-Refractory Prostate Cancer PVI, PeerView Institute for Medical Education Please be sure to view the accompanying (PDF) file or full CME/CE information. In this activity, experts in the treatment of hormone-refractory prostate cancer present recent data on chemotherapeutic regimens, selection of patients for treatment, and prognostic factors for survival. Multidisciplinary management of this condition is also discussed. http://podcast.peerviewpress.com/Urology/PA03939FCr343.mp3 http://podcast.peerviewpress.com/Urology/PA03939FCr343.mp3 Fri, 19 Oct 2007 13:52:44 -0400 Science & Medicine no 00:40:56 prostate cancer,hormone-refractory rostate cancer, HRPC, hormonal manipulation, androgen deprivation, antiandrogen therapy, orchiectomy,docetaxel, mitoxantrone, estramustine, prednisone CME/CE - Educational Interventions to Improve Outcomes in the Multidisciplinary Treatment of Hormone-Refractory Prostate Cancer PVI, PeerView Institute for Medical Education Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. Please view this PDF file or full CME/CE information. You will need Adobe Acrobat reader software to access this file. http://podcast.peerviewpress.com/Urology/PA03939FCCMEinfo.pdf http://podcast.peerviewpress.com/Urology/PA03939FCCMEinfo.pdf Fri, 19 Oct 2007 13:52:38 -0400 Science & Medicine no 00:00:00 CME, Medical Education, continuing medical education, CME credits, PeerView Press, inSession, inReview, CE